First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 38.7 CNY -0.9%
Updated: May 14, 2024

Tibet Rhodiola Pharmaceutical Holding Co
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tibet Rhodiola Pharmaceutical Holding Co
Cost of Revenue Peer Comparison

Comparables:
1099
601607
600998
C
600511
000963

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Cost of Revenue
-¥158.7m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
18%
Sinopharm Group Co Ltd
HKEX:1099
Cost of Revenue
-¥542.6B
CAGR 3-Years
-12%
CAGR 5-Years
-12%
CAGR 10-Years
-15%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Cost of Revenue
-¥229.3B
CAGR 3-Years
-12%
CAGR 5-Years
-11%
CAGR 10-Years
-13%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Cost of Revenue
-¥137.1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
-15%
C
China National Medicines Corp Ltd
SSE:600511
Cost of Revenue
-¥45.7B
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
-17%
Huadong Medicine Co Ltd
SZSE:000963
Cost of Revenue
-¥27.6B
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
-8%

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue?
Cost of Revenue
-158.7m CNY

Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue amounts to -158.7m CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
18%

Over the last year, the Cost of Revenue growth was 23%. The average annual Cost of Revenue growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 7% over the past three years , 5% over the past five years , and 18% over the past ten years .